These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 37421947)

  • 1. Single-cell dissection of Merkel cell carcinoma heterogeneity unveils transcriptomic plasticity and therapeutic vulnerabilities.
    Das BK; Kannan A; Velasco GJ; Kunika MD; Lambrecht N; Nguyen Q; Zhao H; Wu J; Gao L
    Cell Rep Med; 2023 Jul; 4(7):101101. PubMed ID: 37421947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.
    Knepper TC; Montesion M; Russell JS; Sokol ES; Frampton GM; Miller VA; Albacker LA; McLeod HL; Eroglu Z; Khushalani NI; Sondak VK; Messina JL; Schell MJ; DeCaprio JA; Tsai KY; Brohl AS
    Clin Cancer Res; 2019 Oct; 25(19):5961-5971. PubMed ID: 31399473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HDAC Inhibitor Domatinostat Promotes Cell-Cycle Arrest, Induces Apoptosis, and Increases Immunogenicity of Merkel Cell Carcinoma Cells.
    Song L; Bretz AC; Gravemeyer J; Spassova I; Muminova S; Gambichler T; Sriram A; Ferrone S; Becker JC
    J Invest Dermatol; 2021 Apr; 141(4):903-912.e4. PubMed ID: 33002502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study.
    Stege HM; Haist M; Schultheis S; Fleischer MI; Mohr P; Ugurel S; Terheyden P; Thiem A; Kiecker F; Leiter U; Becker JC; Meissner M; Kleeman J; Pföhler C; Hassel J; Grabbe S; Loquai C
    Cancer Immunol Immunother; 2021 Nov; 70(11):3313-3322. PubMed ID: 33870464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for Merkel Cell Carcinoma.
    Nagase K; Narisawa Y
    Curr Treat Options Oncol; 2018 Sep; 19(11):57. PubMed ID: 30238195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the epigenetic addiction of Merkel cell carcinoma.
    Mauri F; Blanpain C
    EMBO Mol Med; 2020 Nov; 12(11):e13347. PubMed ID: 33063436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma.
    Garcia-Carbonero R; Marquez-Rodas I; de la Cruz-Merino L; Martinez-Trufero J; Cabrera MA; Piulats JM; Capdevila J; Grande E; Martin-Algarra S; Berrocal A
    Oncologist; 2019 Oct; 24(10):1375-1383. PubMed ID: 30962295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LSD1 inhibition induces differentiation and cell death in Merkel cell carcinoma.
    Leiendecker L; Jung PS; Krecioch I; Neumann T; Schleiffer A; Mechtler K; Wiesner T; Obenauf AC
    EMBO Mol Med; 2020 Nov; 12(11):e12525. PubMed ID: 33026191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on Merkel Cell Carcinoma.
    Harms PW
    Clin Lab Med; 2017 Sep; 37(3):485-501. PubMed ID: 28802497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for Merkel cell carcinoma: a turning point in patient care.
    Chan IS; Bhatia S; Kaufman HL; Lipson EJ
    J Immunother Cancer; 2018 Mar; 6(1):23. PubMed ID: 29566749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and preclinical treatment options for Merkel cell carcinoma.
    Celikdemir B; Houben R; Kervarrec T; Samimi M; Schrama D
    Expert Opin Biol Ther; 2023; 23(10):1015-1034. PubMed ID: 37691397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade.
    Tabachnick-Cherny S; Pulliam T; Rodriguez HJ; Fan X; Hippe DS; Jones DC; Moshiri AS; Smythe KS; Kulikauskas RM; Zaba LC; Paulson KG; Nghiem P
    Clin Cancer Res; 2024 Mar; 30(6):1189-1199. PubMed ID: 37851052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma.
    Spassova I; Ugurel S; Kubat L; Zimmer L; Terheyden P; Mohr A; Björn Andtback H; Villabona L; Leiter U; Eigentler T; Loquai C; Hassel JC; Gambichler T; Haferkamp S; Mohr P; Pfoehler C; Heinzerling L; Gutzmer R; Utikal JS; Horny K; Schildhaus HU; Habermann D; Hoffmann D; Schadendorf D; Becker JC
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35074902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts.
    Fang B; Kannan A; Zhao S; Nguyen QH; Ejadi S; Yamamoto M; Camilo Barreto J; Zhao H; Gao L
    Sci Rep; 2020 Jun; 10(1):8867. PubMed ID: 32483262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral Status Predicts the Patterns of Genome Methylation and Decitabine Response in Merkel Cell Carcinoma.
    Harms PW; Verhaegen ME; Vo JN; Tien JC; Pratt D; Su F; Dhanasekaran SM; Cao X; Mangelberger D; VanGoor J; Choi JE; Ma VT; Dlugosz AA; Chinnaiyan AM
    J Invest Dermatol; 2022 Mar; 142(3 Pt A):641-652. PubMed ID: 34474081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immune checkpoint inhibition in Merkel cell carcinoma].
    Terheyden P; Mohr A; Langan EA
    Hautarzt; 2019 Sep; 70(9):684-690. PubMed ID: 31468071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma.
    Gaiser MR; Bongiorno M; Brownell I
    Expert Rev Clin Pharmacol; 2018 Apr; 11(4):345-359. PubMed ID: 29478343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options.
    Gehrcken L; Sauerer T; Schaft N; Dörrie J
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma.
    Ananthapadmanabhan V; Frost TC; Soroko KM; Knott A; Magliozzi BJ; Gokhale PC; Tirunagaru VG; Doebele RC; DeCaprio JA
    JCI Insight; 2022 Jul; 7(13):. PubMed ID: 35801592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunobiology of Merkel cell carcinoma.
    Samimi M; Kervarrec T; Touze A
    Curr Opin Oncol; 2020 Mar; 32(2):114-121. PubMed ID: 31972727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.